Foghorn Therapeutics Surges 7.5% as 2026 Phase II Readouts Loom
Foghorn Therapeutics’ share price climbs 7.5%, backed by a Phase II oncology pipeline, strong cash reserves, and a potential 2027 market entry.
- FOGHORN THERAPEUTICS INC
- United States
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- AI generated
3 minutes to read